{"id":16291,"name":"SCI Ventures","slug":"sci-ventures","website":"https://www.sciventures.com/","hqGeo":null,"stageFocus":["Pre-Seed","Seed","Series A"],"sectorTags":["Healthcare","AI / ML","SaaS"],"excludedSectors":[],"checkSizeMin":null,"checkSizeMax":null,"thesisSummary":"A specialist venture philanthropy fund dedicated to paralysis, neuro-restoration, and cure-oriented therapies. It backs early-stage technologies and treatments that restore function for people living with spinal cord injury and related neurologic impairment.","thesisNarrative":null,"logoUrl":null,"aumUsd":null,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"ViaNautis","companyUrl":null,"stage":null,"sector":"Nano & genetic medicine","investmentYear":null,"description":"Targeted delivery of regenerative cargo to the brain and specific tissues has been a major challenge in central nervous-system repair.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"NervGen Pharma","companyUrl":null,"stage":null,"sector":"Peptide drugs","investmentYear":null,"description":"NervGen Pharma (NASDAQ: NGEN) is developing drug treatments that allow the central nervous system to regenerate itself.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Axonis","companyUrl":null,"stage":null,"sector":"Small molecule drugs","investmentYear":null,"description":"Axonis Therapeutics is developing medicines for neuron restoration and neuromodulation.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Cyllene Therapeutics","companyUrl":null,"stage":null,"sector":"Gene therapy","investmentYear":null,"description":"Cyllene Therapeutics (formerly: EG 427) has developed a platform technology to create targeted gene therapies tailored to specific neuronal populations.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Healx","companyUrl":null,"stage":null,"sector":"Small molecules & AI drug discovery","investmentYear":null,"description":"Healx is one of the few AI-based discovery companies that have successfully shown the power of their approach across multiple indications.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Precision Neuroscience","companyUrl":null,"stage":null,"sector":"Brain-computer interface","investmentYear":null,"description":"Precision Neuroscience was founded to create the next generation of brain-computer interfaces to restore interaction with the environment.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Sania Therapeutics","companyUrl":null,"stage":null,"sector":"Gene therapy / SMD","investmentYear":null,"description":"Sania has developed a gene-therapy platform to selectively target dysfunctional neural circuits.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Onward Medical","companyUrl":null,"stage":null,"sector":"Electrical stimulation / BCI","investmentYear":null,"description":"Onward is the leader in the spinal cord stimulation space, focusing on targeted, programmed stimulation of the spinal cord.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Augmental","companyUrl":null,"stage":null,"sector":"Assistive","investmentYear":null,"description":"Augmental has developed the MouthPad: an in-mouth interface for hands-free human-computer interaction.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Axonis Therapeutics","companyUrl":null,"stage":"Early-stage; preclinical / planned clinical trial window referenced.","sector":"Biotech / neurotherapeutics","investmentYear":null,"description":"Developing medicines for neuron restoration and neuromodulation.","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":6,"partners":[{"id":53135,"name":"Roman Rothaermel, PhD","title":"Investment Principal","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Biotech Operator, PhD Neuroscience University of Oxford","recentPosts":[]},{"id":53065,"name":"Roman Rothaermel","title":"Principal","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/rrothaermel","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":53066,"name":"Not disclosed","title":"GP","seniority":null,"focusTags":["Neuro-restoration","Paralysis","Early-stage therapeutics"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":53132,"name":"Tom Londres","title":"Board Member","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Board Member, Reeve Foundation CEO, Metro Commercial, Inc.","recentPosts":[]},{"id":53133,"name":"Ian Curtis","title":"Board Member","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":"Board Member, ISRT and Reeve Foundation Chairman, HPC plc, Former PwC Partner","recentPosts":[]},{"id":53134,"name":"Adrien Cohen","title":"Founding Managing Director, Board & Investment Committee Member","seniority":null,"focusTags":[],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsThisYear":0},"activityItems":[],"contentUpdatedAt":null,"investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":7722,"name":"Sheesha Finance","slug":"sheesha-finance","logoUrl":null,"website":"https://sheeshafinance.gitbook.io/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Fintech"],"hqGeo":null},{"id":13762,"name":"NeuroNet Ventures","slug":"neuronet-ventures","logoUrl":null,"website":"https://neuronetgpo.com/","stageFocus":["Seed"],"sectorTags":["AI / ML"],"hqGeo":"Chicago, IL"},{"id":11767,"name":"LiftScale Partners","slug":"liftscale-partners","logoUrl":null,"website":"https://weareliftscale.com/","stageFocus":["Pre-Seed"],"sectorTags":["AI / ML","SaaS"],"hqGeo":"San Francisco, CA"},{"id":547,"name":"Cocoa VC","slug":"cocoa-vc","logoUrl":null,"website":"https://www.cocoa.vc/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Fintech","SaaS"],"hqGeo":"San Francisco, CA"},{"id":1574,"name":"Plaid Ventures","slug":"plaid-ventures","logoUrl":null,"website":"https://plaid.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Fintech","Developer Tools","AI / ML"],"hqGeo":"San Francisco, CA"},{"id":12955,"name":"Jovono","slug":"jovono","logoUrl":null,"website":"https://jovono.com","stageFocus":["Seed","Series A"],"sectorTags":["Climate / Energy","Fintech","Consumer","SaaS","Healthcare"],"hqGeo":"Los Angeles, CA"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"saas","displayName":"SaaS Investors","pageType":"industry"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"ai","displayName":"AI & ML Investors","pageType":"industry"},{"slug":"series-a","displayName":"Series A Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"how-to-find-investors","title":"How to Find Investors: A VC's Playbook for Founders"},{"slug":"how-vcs-help-portfolio-raise-follow-on","title":"How VCs Can Actually Help Their Portfolio Companies Raise Follow-On"},{"slug":"how-many-investors-should-you-pitch","title":"How Many Investors Should You Pitch? The Math Most Founders Get Wrong"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-10-28T01:00:11.962Z"}